NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring (TDM) of individual patients, and the assessment of drug diversion of a new pain management drug therapy.
NMS Labs is the only known commercial laboratory to develop and perform a clinical quantitative assay for Milnacipran (Savella®) using the highly specific and sensitive technique of liquid chromatography/tandem mass spectrometry (LC-MS/MS).
Eric Rieders, PhD, President and CEO expressed the importance of innovation at NMS Labs by saying, “We best serve the medical community by deploying our professional and technical resources to rapidly identify and develop diagnostic tests within our area of expertise that might otherwise only become available at a much later date.” Dr Rieders added, “NMS Labs is well known for providing the rare and hard to find tests that other labs do not.”
NMS Labs has responded to the need of the pain management community by filling a void in testing options. Milnacipran is a new medication used for the treatment of pain associated with fibromyalgia. NMS Labs specializes in testing for various classes of pharmacological agents, including: analgesics; anesthetics; anticonvulsants; antidepressants; hallucinogens; muscle relaxants; NSAIDs; opioids; sedatives and hypnotics; sleep aids; and stimulants.
Source: NMS Labs
